All In Biotech

Drug Trial Radar · NCT04038502

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

An Open-label, Multicenter Phase II Study to Compare the Efficacy of Carboplatin as First-line Followed by Second-line Olaparib Versus Olaparib as First-line Followed by Second-line Carboplatin in the Treatment of Patients With Castration Resistant Prostate Cancer Containing Homologous Recombination Deficiency

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Oct 1, 2019

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Jul 30, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. Participants are randomized (1:1) and receive either carboplatin (AUC 5, IV) every 21 days, first or olaparib taken orally (300 mg), twice daily in 28 day cycles, until intolerance, complete response, or progression by Prostate Cancer Working Group 3 (PCWG3) criteria. Participants then crossover from the first-line therapy to the second-line therapy with the opposite study medication and receive treatment to intolerance or progression (whichever is first). Enrolled participants will be allowed to crossover to second line therapy if they continue to meet initial eligibility criteria, and at least three weeks have elapsed since last administration of either carboplatin or olaparib. Throughout the study, safety and tolerability will be assessed. Progression will be evaluated with bone scan, CT of the abdomen/pelvis, or MRI and PSA as per PCWG3 criteria.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer
  • BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2
  • RAD51B, RAD51C, RAD51D, or RAD54L Mutations

Interventions

  • CarboplatinDrug

    Chemotherapy FDA approved drug used to treat: ovarian, lung, head and neck cancers. It is sometimes used in combination with other medications or off-label use to treat other metastatic cancers.

  • OlaparibDrug

    Olaparib is a targeted therapy drug that is used for mCRPC and is approved by the FDA for this use.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS-1L) defined as the time interval between randomization and first documented disease progression or death due to any cause reported during, or after, first-line treatmentTime frame: Through duration of the study, up to 100 weeks

Locations

18 sites in 1 country. Site status is shown where the registry gives one.

  • VA Greater Los Angeles Healthcare System, West Los Angeles, CA

    West Los Angeles, California · Recruiting

  • Rocky Mountain Regional VA Medical Center, Aurora, CO

    Aurora, Colorado · Recruiting

  • Washington DC VA Medical Center, Washington, DC

    Washington D.C., District of Columbia · Recruiting

  • Bay Pines VA Healthcare System, Pay Pines, FL

    Bay Pines, Florida · Terminated

  • Orlando VA Medical Center, Orlando, FL

    Orlando, Florida · Recruiting

  • Atlanta VA Medical and Rehab Center, Decatur, GA

    Decatur, Georgia · Recruiting

  • Boise VA Medical Center, Boise, ID

    Boise, Idaho · Recruiting

  • Jesse Brown VA Medical Center, Chicago, IL

    Chicago, Illinois · Terminated

  • VA Ann Arbor Healthcare System, Ann Arbor, MI

    Ann Arbor, Michigan · Recruiting

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota · Recruiting

  • Kansas City VA Medical Center, Kansas City, MO

    Kansas City, Missouri · Recruiting

  • Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY

    New York, New York · Recruiting

  • James J. Peters VA Medical Center, Bronx, NY

    The Bronx, New York · Terminated

  • Durham VA Medical Center, Durham, NC

    Durham, North Carolina · Recruiting

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon · Recruiting

  • Philadelphia MultiService Center, Philadelphia, PA

    Philadelphia, Pennsylvania · Recruiting

  • VA Puget Sound Health Care System Seattle Division, Seattle, WA

    Seattle, Washington · Recruiting

  • William S. Middleton Memorial Veterans Hospital, Madison, WI

    Madison, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.